Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease (ASPIRE)

Cardium Therapeutics

Status and phase

Terminated

Phase 3

Conditions

Angina, Stable

Treatments

Genetic: Alferminogene tadenovec

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT01550614

CT-3-002

Details and patient eligibility

About

The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4, delivered during induced transient ischemia, is effective in improving myocardial perfusion, angina functional class, patient symptoms, and quality of life. Short-term (8 weeks) and long-term (12 month) safety of Ad5FGF-4 will also be evaluated. The primary endpoint is change in adenosine triphosphate (ATP) stress SPECT reperfusion defect size.

Enrollment

11 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients 18-75 years of age, inclusive
Postmenopausal female patients, women of childbearing potential and men willing to use an effective contraception method while on the study treatment and/or who agree not to become pregnant or make their partner pregnant throughout the study and during one year after administration of the study drug
Female subjects of childbearing potential who have a negative urine pregnancy test, and are willing to use an acceptable form of birth control during the study
Diagnostic coronary angiogram in the past confirming the presence of coronary artery disease. Patients with extensive disease, or high risk for intervention, or who don't want the higher risk angioplasty or surgery, or have had angioplasty with recurrent angina and vessels are not ideal for angioplasty are ideal candidates
Stable angina pectoris being treated with chronic anti-anginal medication(s) at a stable dose for 2 weeks prior to randomization
Left ventricular ejection fraction (LVEF) of ≥30%. If the LVEF is <30% the patient can be enrolled if there is no recent or current congestive heart failure present
Evidence of stress induced myocardial ischemia by ATP technetium-99m sestamibi SPECT, defined as a reversible perfusion defect size of ≥9%
Willing and able to comply with the study requirements
Provided written informed consent

Exclusion criteria

Female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study and one year after administration of the study drug. Women of child bearing potential who are not using an acceptable method of birth control. Women of child bearing potential with a positive urine pregnancy test within 24 hours prior to the start of investigational product
Patients with unstable angina for whom an immediate revascularization procedure is indicated
Patients for whom a cardiac revascularization procedure is planned in the next 3 months
Myocardial infarction within the 3 months prior to the Screening visit
Congestive heart failure NYHA Class IV
Myocarditis or restrictive pericarditis
Left main coronary stenosis ≥70% (unless the patient has a patent graft or collateral vessels supplying the left coronary circulation) or proximal stenoses ≥70% in all major coronary conduit vessels (coronary arteries and bypass grafts)
A single patent coronary conduit (for example, totally occluded RCA and LCx with no bypass grafts. Patient will not tolerate balloon occlusion of the LAD for infusion)
Clinically significant aortic or mitral valvular heart disease.
Life threatening coronary ostial stenosis that precludes adequate catheter engagement in any target vessel, unless the vessel can be accessed via a patent bypass graft
Coronary artery to venous communications, which bypass the coronary capillary bed
Untreated life-threatening ventricular arrhythmias
Uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic pressure >100 mm Hg
CABG surgery within the past 6 months, unless those grafts are now occluded
Percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months, unless the stented/dilated vessel(s) are now occluded
Enhanced external counterpulsation (EECP) within 3 months prior to the start of screening evaluations
Transmyocardial or percutaneous myocardial laser revascularization within the previous year
Prior treatment with any cardiovascular gene therapy
Patients who received an investigational drug or biologic within 30 days of screening or are currently participating in an investigational drug, biologic or device trial